Triamcinolone hexacetonide
Aristospan (triamcinolone hexacetonide) is a small molecule pharmaceutical. Triamcinolone hexacetonide was first approved as Aristospan on 1982-01-01. It is used to treat adrenal insufficiency, allergic rhinitis perennial, ankylosing spondylitis, atopic dermatitis, and berylliosis amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Show 7 more
Trade Name
FDA
EMA
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| hexatrione | unapproved drug for use in drug shortage | 2026-05-26 |
Indications
FDA
EMA
Show 17 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
Code | Description |
|---|---|
| J3303 | Injection, triamcinolone hexacetonide, per 5 mg |
Clinical
Clinical Trials
1119 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Macular edema | D008269 | — | — | 14 | 21 | 27 | 7 | 21 | 82 |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | 6 | 18 | 13 | 26 | 22 | 78 |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | 6 | 17 | 11 | 23 | 24 | 78 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 21 | 18 | 1 | 11 | 48 |
| Edema | D004487 | — | R60.9 | 10 | 14 | 14 | 3 | 11 | 47 |
| Bursitis | D002062 | EFO_1000941 | M71.9 | 2 | 1 | 2 | 5 | 36 | 46 |
| Oral lichen planus | D017676 | — | — | 11 | 9 | 4 | 10 | 9 | 40 |
| Keloid | D007627 | EFO_0004212 | L91.0 | 4 | 9 | 4 | 9 | 14 | 36 |
| Lichen planus | D008010 | — | L43 | 8 | 6 | 2 | 6 | 8 | 29 |
| Kidney transplantation | D016030 | — | — | 2 | 12 | 3 | 9 | 3 | 27 |
Show 175 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 7 | 9 | 2 | — | 3 | 17 |
| Graft vs host disease | D006086 | — | D89.81 | 2 | 6 | 3 | — | 2 | 12 |
| Leukemia | D007938 | — | C95 | 4 | 7 | 1 | — | — | 11 |
| Myelodysplastic syndromes | D009190 | — | D46 | 1 | 6 | 2 | — | — | 9 |
| Hodgkin disease | D006689 | — | C81 | 3 | 5 | 2 | — | — | 8 |
| Cicatrix | D002921 | — | L90.5 | 1 | 2 | 1 | — | 5 | 8 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 3 | 4 | 1 | — | — | 7 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 1 | 5 | 2 | — | 1 | 7 |
| Posterior uveitis | D015866 | EFO_1001119 | — | 1 | 2 | 2 | — | 2 | 6 |
| Gouty arthritis | D015210 | — | — | — | 1 | 4 | — | — | 5 |
Show 76 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asthma | D001249 | EFO_0000270 | J45 | — | 2 | — | — | 4 | 6 |
| T-cell lymphoma | D016399 | — | — | 1 | 5 | — | — | — | 6 |
| Aphthous stomatitis | D013281 | EFO_0003938 | K12.0 | — | 3 | — | — | 2 | 5 |
| T-cell lymphoma cutaneous | D016410 | — | C84.A | 1 | 2 | — | — | 1 | 4 |
| Oral ulcer | D019226 | — | — | — | 1 | — | — | 3 | 4 |
| Therapeutics | D013812 | — | — | — | 1 | — | — | 2 | 3 |
| T-cell lymphoma peripheral | D016411 | — | — | — | 3 | — | — | — | 3 |
| Triple negative breast neoplasms | D064726 | — | — | — | 2 | — | — | 1 | 3 |
| Male breast neoplasms | D018567 | — | — | — | 1 | — | — | 2 | 3 |
| Hematologic neoplasms | D019337 | — | — | 1 | 2 | — | — | — | 3 |
Show 80 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuralgia | D009437 | EFO_0009430 | — | 1 | — | — | — | 3 | 4 |
| Paranasal sinus diseases | D010254 | — | — | 1 | — | — | — | 1 | 2 |
| Glandular and epithelial neoplasms | D009375 | — | — | 2 | — | — | — | — | 2 |
| Myoepithelioma | D009208 | — | — | 2 | — | — | — | — | 2 |
| Leiomyoma | D007889 | — | D25 | 1 | — | — | — | — | 1 |
| Adenomyosis | D062788 | EFO_1001757 | N80.0 | 1 | — | — | — | — | 1 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 1 | — | — | — | — | 1 |
| Vasoconstriction | D014661 | — | — | 1 | — | — | — | — | 1 |
| Papilledema | D010211 | EFO_1001074 | H35.81 | 1 | — | — | — | — | 1 |
| Acoustic neuroma | D009464 | — | — | 1 | — | — | — | — | 1 |
Show 10 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | — | — | — | 7 | 7 |
| Membranous glomerulonephritis | D015433 | EFO_0004254 | N03.2 | — | — | — | — | 5 | 5 |
| Retinal perforations | D012167 | EFO_1001028 | — | — | — | — | — | 5 | 5 |
| Mastitis | D008413 | EFO_1001034 | N61 | — | — | — | — | 4 | 4 |
| Periodontal diseases | D010510 | — | K05.6 | — | — | — | — | 4 | 4 |
| Granulomatous mastitis | D058890 | — | N61.2 | — | — | — | — | 3 | 3 |
| Physical therapy modalities | D026741 | — | — | — | — | — | — | 3 | 3 |
| Rehabilitation | D012046 | — | — | — | — | — | — | 3 | 3 |
| Peripheral nervous system diseases | D010523 | — | G64 | — | — | — | — | 3 | 3 |
| Acne vulgaris | D000152 | EFO_0003894 | L70 | — | — | — | — | 3 | 3 |
Show 154 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Triamcinolone hexacetonide |
| INN | triamcinolone hexacetonide |
| Description | Triamcinolone hexacetonide is a corticosteroid hormone. |
| Classification | Small molecule |
| Drug class | steroids (not prednisolone derivatives); topical steroids (acetal derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)(C)CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C |
Identifiers
| PDB | — |
| CAS-ID | 5611-51-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200878 |
| ChEBI ID | 9670 |
| PubChem CID | 21826 |
| DrugBank | — |
| UNII ID | I7GT1U99Y9 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 102 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
204 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use